2022年

発表

1. 榮枝一磨,定平卓也,丸山雄樹,岩田健宏,荒木元朗,石井亜矢乃,渡邉豊彦,那須保友,和田耕一郎：尿から分離されたESBL産生大腸菌株の性状解析を踏まえたFMOXの使用法．第70回日本化学療法学会総会．岐阜，2022.6
2. 丸山雄樹,定平卓也,榮枝一磨,石井亜矢乃,和田耕一郎：当院におけるプロテウス菌の抗菌薬感受性の年次推移および結石形成能．第70回日本化学療法学会総会．岐阜，2022.6
3. 和田耕一郎：島根大学における医療安全対策 ～ロボット支援手術と腎移植を中心に～．令和4年度日本医師会生涯教育講座．松江，2022.12
4. 和田耕一郎：泌尿器科領域における感染症の現状と展望．第6回札幌尿路感染症研究会．札幌，2022.3
5. 和田耕一郎：単純性膀胱炎におけるAMRの現状と対策．第92回日本感染症学会西日本地方会学術集会/第65回日本感染症学会中日本地方会学術集会/第70回日本化学療法学会西日本支部総会 合同学会（シンポジウム）．長崎，2022.11
6. 和田耕一郎,坪井一朗,小川貢平,吉岡彩織,横山周平,小林祐介,中島宏親,永見太一,山崎清玄,安食春輝,小池千明,安本博晃,本田聡,椎名浩昭：島根大学泌尿器科の手術関連統計2021年．第330回日本泌尿器学会岡山地方会．Web，2022.2
7. 和田耕一郎：性感染症 診断と治療 Up to date．第72回日本泌尿器科学会中部総会（卒後教育プログラム）．和歌山，2022.10
8. 和田耕一郎,小川貢平,坪井一朗,吉岡彩織,横山周平,小林祐介,中島宏親,永見太一,小池千明,椎名浩昭：本邦におけるM. genitalium感染症の現状と課題．日本性感染症学会 第35回学術大会（シンポジウム）．北九州，2022.12
9. 和田耕一郎,永見太一,吉岡彩織,横山周平,小林祐介,坪井一朗,中島宏親,小川貢平,小池千明：HIVを含む複数の性感染症を伴った陰茎コンジローマ様癌の一例．日本性感染症学会 第35回学術大会．北九州，2022.12
10. 坪井一朗,吉岡彩織,横山周平,小林祐介,中島宏親,小池千明,永見太一,小川貢平,和田耕一郎：回腸尿管吻合部閉塞に対する“Cut-to-the-light technique”：適応と手技に関する考察．第36回日本泌尿器内視鏡・ロボティクス学会総会．Web，2022.11
11. 和田耕一郎:島根大学病院だから提供できる安全な低侵襲手術の実際．松江市民フォーラム「島根大学病院の最新治療」（市民公開講座）．松江，2022.10

論文

1. Tominaga Y, Fujii M, Sadahira T, Katayama S, Iwata T, Nishimura S, Bekku K, Edamura K, Kobayashi T, Kobayashi Y, Kiura K, Maeda Y, Wada K, Araki M: Bladder tuberculosis with ureteral strictures after bacillus Calmette Guérin therapy for urinary bladder cancer: A case report. Mol Clin Oncol. 2022 Dec 20;18(2):7.
2. Watanabe T, Sako T, Tominaga Y, Sadahira T, Sekito T, Takamoto A, Edamura K, Kobayashi Y, Wada K, Araki M: A case of tape infection 19 years after insertion of a tension-free vaginal tape sling. IJU Case Rep. 2022 Mar 28;5(4):228-231.
3. Yokoyama S, Tsuboi I, Ogawa K, Yoshioka S, Kobayasi Y, Nakajima H, Nagami T, Yamasaki S, Wada K: Isolated rupture of the corpus spongiosum with urethral injury diagnosed by pre-surgical MRI. IJU Case Rep. 2022 Nov 22;6(1):70-72.
4. Tohi Y, Kato T, Fukuhara H, Kobayashi K, Ohira S, Ikeda K, Daizumoto K, Katayama S, Shimizu R, Nishimura K, Nagami T, Hayashida Y, Hirama H, Takamoto A, Dainichi T, Sugimoto M; Chu-shikoku Japan Urological Consortium: Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium. Int J Clin Oncol. 2022 Aug;27(8):1348-1355.
5. Sekito T, Araki M, Wada K, Yoshinaga K, Maruyama Y, Sadahira T, Katayama S, Iwata T, Nishimura S, Sako T, Edamura K, Kobayashi Y, Watanabe T: A Novel Technique Using Fluorescent Ureteral Catheter and Flexible Ureteroscope for Safe Laparoscopic Fenestration of Lymphocele after Kidney Transplantation. Case Rep Transplant. 2022 Feb 7;2022:9948425.
6. Acosta H, Sadahira T, Sekito T, Maruyama Y, Iwata T, Araki M, Ogawa K, Tsuboi I, Wada K: Post-prostate biopsy acute bacterial prostatitis and screening cultures using selective media: An overview. Int J Urol. 2022 Jun;29(6):486-493.
7. Ichihara K, Takahashi S, Hiyama Y, Masumori N, Nagae H, Ito S, Wada K, Betsunoh H, Hamasuna R, Togo Y, Shigemura K, Takeyama K: Distribution of the positive UPOINT domain in patients with chronic prostatitis or chronic pelvic pain syndrome: A multicenter observational study. J Infect Chemother. 2022 May;28(5):631-634.
8. Matsuzaki J, Takahashi S, Yamaguchi A, Wada K, Miyazaki J, Mugiya S, Matsuda T, Nutahara K, Seki S, Morimoto T, Yamamoto S: Japanese linguistic validation of the ureteral stent symptom questionnaire. Int J Urol. 2022 Apr;29(4):332-336.
9. Tsuboi I, Ogawa K, Wada K: Editorial Comment to Rare case of retropubic parasymphyseal cyst in a male patient. IJU Case Rep. 2021 Oct 26;5(1):40.
10. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Place RF, Pookot D, Majid S, Igawa M, Dahiya R: Retraction Note: Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity. Oncogene. 2022 Nov;41(45):4981.
11. Koshiro N, Nakajima K, Oyama M, Kaneko G, Takahashi S, Matsuyama H, Shiina H, Ichikawa T, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Mizokami A; PROSTAT-BSI Investigators: Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer. Int J Urol. 2022 Dec;29(12):1477-1487.
12. Yazaki T, Moriyama I, Tobita H, Sonoyama H, Okimoto E, Oka A, Mishima Y, Oshima N, Shibagaki K, Kawashima K, Ishimura N, Nagami T, Maruyama R, Shiina H, Ishihara S: The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma. Intern Med. 2022 May 15;61(10):1485-1490.
13. Kamijima T, Yaegashi H, Mizokami A, Nakajima K, Matsuyama H, Ichikawa T, Nishimoto K, Takahashi S, Shiina H, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Enokida H: Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis. Anticancer Res. 2022 Jun;42(6):3099-3108.
14. Mizokami A, Nishimoto K, Matsuyama H, Ichikawa T, Takahashi S, Shiina H, Hashine K, Sugiyama Y, Kamiyama M, Enokida H, Nakajima K: Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice. Anticancer Res. 2022 Mar;42(3):1465-1475.
15. Nagumo Y, Onozawa M, Kojima T, Terada N, Shiota M, Mitsuzuka K, Yasumoto H, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Saito T, Yokomizo A, Kohei N, Tabata KI, Takahashi A, Sugimoto M, Kitamura H, Kamoto T, Nishiyama H; Japanese Urological Oncology Group (JUOG): Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden. Int J Urol. 2022 May;29(5):398-405.
16. Iida K, Miyake M, Murakami K, Komiyama M, Okajima E, Sazuka T, Nishiyama N, Yasumoto H, Kimura T, Ito A, Shiga K, Yamagishi A, Kikuchi H, Sugimoto M, Taoka R, Kobayashi T, Kojima T, Kitamura H, Nishiyama H, Fujimoto K: Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy. Int J Clin Oncol. 2021 Nov;26(11):2104-2112.
17. Taoka R, Kobayashi T, Hidaka Y, Abe H, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Kamiyama M, Morita S, Ogawa O, Nishiyama H, Kitamura H, Sugimoto M; Japan Urological Oncology Group: Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma. Urol Oncol. 2022 Mar;40(3):107.e1-107.e9.
18. Miyake M, Iida K, Nishimura N, Inoue T, Matsumoto H, Matsuyama H, Fujiwara Y, Komura K, Inamoto T, Azuma H, Yasumoto H, Shiina H, Yonemori M, Enokida H, Nakagawa M, Fukuhara H, Inoue K, Yoshida T, Kinoshita H, Matsuda T, Fujii T, Fujimoto K; Nishinihon Uro-oncology Extensive Collaboration Group: Site-specific Risk Stratification Models for Postoperative Recurrence and Survival Prediction in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy: Better Stratification for Adjuvant Therapy. Eur Urol Open Sci. 2022 May 30;41:95-104.